Adverse Event Management in HR+/HER2– Advanced Breast Cancer: PI3K/AKT/PTEN Pathway
October 14th 2024Panelists discuss how targeted therapies and effective management of adverse events, particularly in relation to the PI3K/AKT/PTEN pathway, are crucial for optimizing treatment outcomes in hormone receptor (HR)–positive, HER2-negative advanced breast cancer.
Optimizing R/R CLL Treatment: Therapy Sequencing and Supportive Care Strategies
October 8th 2024Nitin Jain, MD, and Joanna M. Rhodes, MD, MDCS, discuss how various aspects of chronic lymphocytic leukemia (CLL) management are approached, including treatment selection based on prior therapies and patient factors, the use of novel agents such as pirtobrutinib, strategies for relapsed/refractory (R/R) disease, treatment sequencing, and the role of multidisciplinary teams in optimizing patient care and outcomes.
Optimizing Care for Lower-Risk Myelodysplastic Syndromes: Translating Evidence to Clinical Practice
September 30th 2024Panelists discuss how recent advances in treating Lower-Risk Myelodysplastic Syndromes have impacted clinical practice, using hypothetical scenarios to demonstrate their approach to incorporating new data into patient care.
Clinical Updates in Treating Advanced Prostate Cancer
September 30th 2024Panelists discuss how advancements in biomarker and genetic testing, along with updated treatment guidelines, are transforming the diagnosis and management of prostate cancer, emphasizing the importance of personalized approaches in optimizing patient outcomes.
Strategies to Manage Antibody Drug Conjugates (ADC) - Related Toxicities in Breast Cancer
August 21st 2024Hope Rugo, MD, FASCO and Aditya Bardia MD, MPH, FASCOexplore strategies for managing antibody drug conjugate (ADC)-related toxicities in breast cancer, covering current ADCs, real-world management practices, and future directions, in this OncLive Insights video series.
My Treatment Approach: Optimizing Treatment for Chronic GVHD
August 21st 2024This educational program, led by experts Shernan Holtan, MD, and Haris Ali, MD, explores the latest strategies and emerging treatments for optimizing management of chronic graft-vs-host disease (cGVHD), including monitoring techniques, therapeutic options, and patient-reported outcomes.
Novel Breakthroughs in Management of Pediatric Low-Grade Glioma (pLGG)
July 15th 2024Pediatric low-grade glioma specialists examine recent therapeutic advancements and their practical implications, presenting two real-world cases to demonstrate the integration of new data into clinical decision-making.
Focus on Pathways: Targeting the CSF-1R Pathway in Graft-vs-Host Disease
July 8th 2024Hannah Choe, MD discusses the role of the CSF-1 receptor (CSF-1R) pathway in the pathogenesis of graft-versus-host disease (GVHD) and other diseases. She reviews the rationale for targeting this pathway as a therapeutic strategy and examines preclinical and clinical data on the use of CSF-1R inhibitors, such as axatilimab, for the treatment of GVHD. Dr. Choe provides insights on the practical considerations for integrating these novel agents into clinical practice.
My Treatment Approach: Improving Chronic Lymphocytic Leukemia Management and Treatment Outcomes
June 25th 2024A panel of experts on chronic lymphocytic leukemia review patient cases, discuss the latest research presented at ASCO 2024 and surrounding meetings, and provide insights on evolving clinical practices.
Optimizing Treatment Strategies for HR+/HER2- Breast Cancer: ESR1 Mutations and Emerging Therapies
June 19th 2024Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, explore the evolving landscape of HR+/HER2- metastatic breast cancer management, focusing on the clinical implications of ESR1 and PIK3CA mutations, the role of biomarker testing, the impact of novel therapies and combination strategies, and the importance of personalized treatment approaches in improving patient outcomes.
Targeting the PI3K/AKT/PTEN Pathway in HR+/HER2- Locally Advanced and Metastatic Breast Cancer
June 10th 2024Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, provide valuable insights into targeting the PI3K/AKT/PTEN pathway, exploring mechanisms of resistance, adverse event profiles, and treatment decision-making strategies for patients with HR+/HER2- locally advanced and metastatic breast cancer.
ASK THE EXPERTS: Advanced Neuroimaging of Glioblastoma
May 23rd 2024Nathalie Albert, MD, and Matthias Preusser, MD, explore the latest advancements in neuroimaging technologies and techniques, focusing on the use of amino acid tracers to enhance the diagnosis, treatment, and overall care of patients with glioblastoma.
My Treatment Approach: HER2+ Breast Cancer
May 17th 2024Tiffany A. Traina, MD; Vijayakrishna Gadi, MD, PhD, and Heather McArthur, MD, explore the current treatment landscape for HER2-positive metastatic breast cancer. They discuss standard of care therapies across lines, pivotal trial data, management of brain metastases, optimal sequencing strategies after, and emerging novel agents. Two patient cases help illustrate real-world decision-making.
Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting
March 27th 2024Medical experts discuss the evolving treatment landscape and adverse events associated with 3L colorectal cancer treatment.
Funding supported by Taiho Oncology. Content independently developed by OncLive.
Optimizing Patient Outcomes in High-Risk HR+, HER2- Early-Stage Breast Cancer
March 25th 2024Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, provide a comprehensive analysis of risk stratification in high-risk HR+/HER2- early-stage breast cancer, clinical approaches with high-risk breast cancer, recent trial data with CDK4/6 inhibitors, and strategies for managing toxicities for treatment continuity in the management of HR+/HER2- early-stage breast cancer, offering valuable insights to optimize patient care.
Year in Review: Updates in Treating Myelofibrosis
March 6th 2024Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, discuss the nuanced treatment landscape of myelofibrosis, exploring the latest advancements in JAK inhibitors, the importance of individualized care, and the potential of emerging combination therapies to enhance patient outcomes.